{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:10:16Z","timestamp":1780416616440,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009009","name":"Novartis Pharmaceuticals Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.msard.2026.106976","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:14:28Z","timestamp":1767716068000},"page":"106976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A real-world study on persistence with ofatumumab in Canadian patients with multiple sclerosis"],"prefix":"10.1016","volume":"107","author":[{"given":"Daniel","family":"Selchen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Magnussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calum S","family":"Neish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17_supplement_2","key":"10.1016\/j.msard.2026.106976_bib0010","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1212\/WNL.0000000000203074","article-title":"Compliance and persistence with Ofatumumab treatment in patients with relapsing multiple sclerosis in clinical trials for up to 4 years (P8-3.002)","volume":"100","author":"Alvarez","year":"2023","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2026.106976_bib0009","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40263-021-00843-8","article-title":"Clinical perspectives on the molecular and pharmacological attributes of Anti-CD20 therapies for multiple sclerosis","volume":"35","author":"Bar-Or","year":"2021","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.msard.2026.106976_bib0017","first-page":"639","article-title":"Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data","volume":"27","author":"Engmann","year":"2021","journal-title":"J. Manag. Care Spec Pharm"},{"issue":"4","key":"10.1016\/j.msard.2026.106976_bib0002","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1017\/cjn.2020.66","article-title":"Treatment optimization in Multiple sclerosis: canadian MS Working Group recommendations","volume":"47","author":"Freedman","year":"2020","journal-title":"Can. J. Neurol. Sci. J. Can. Sci. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2026.106976_bib0026","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1177\/13524585221078825","article-title":"Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II","volume":"28","author":"G\u00e4rtner","year":"2022","journal-title":"Mult. Scler"},{"issue":"7","key":"10.1016\/j.msard.2026.106976_bib0018","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1007\/s00415-024-12326-z","article-title":"ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial","volume":"271","author":"Hartung","year":"2024","journal-title":"J. Neurol"},{"issue":"6","key":"10.1016\/j.msard.2026.106976_bib0006","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.msard.2026.106976_bib0019","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40120-023-00518-0","article-title":"The development of Ofatumumab, a fully Human anti-CD20 monoclonal antibody for practical use in relapsing multiple sclerosis treatment","volume":"12","author":"Hauser","year":"2023","journal-title":"Neurol. Ther"},{"issue":"4","key":"10.1016\/j.msard.2026.106976_bib0027","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.msard.2026.106976_bib0021","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200410","article-title":"Impact of continuous ofatumumab exposure during pregnancy in multiple sclerosis - PubMed","volume":"15","author":"Hefner","year":"2025","journal-title":"Neurol. Clin. Pract"},{"key":"10.1016\/j.msard.2026.106976_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105888","article-title":"Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis","volume":"91","author":"Hersh","year":"2024","journal-title":"Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.msard.2026.106976_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103860","article-title":"A cross-sectional analysis of persistence to disease-modifying therapies in treatment na\u00efve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy","volume":"63","author":"Kozlicki","year":"2022","journal-title":"Mult. Scler. Relat. Disord"},{"issue":"4","key":"10.1016\/j.msard.2026.106976_bib0023","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","article-title":"Family planning considerations in people with multiple sclerosis","volume":"22","author":"Krysko","year":"2023","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.msard.2026.106976_bib0008","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","article-title":"Anti-CD20 therapies for multiple sclerosis: current status and future perspectives","volume":"269","author":"Margoni","year":"2022","journal-title":"J. Neurol"},{"key":"10.1016\/j.msard.2026.106976_bib0001","unstructured":"Multiple Sclerosis International Federation. Atlas of MS. 3rd edition. (September 2020). https:\/\/www.msif.org\/wp-content\/uploads\/2020\/10\/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf Date Accessed: November 19, 2024."},{"key":"10.1016\/j.msard.2026.106976_bib0011","unstructured":"Multiple Sclerosis International Federation. Atlas of MS, Canada Fact Sheet. https:\/\/atlasofms.org\/fact-sheet\/canada (accessed 19 November 2025)."},{"key":"10.1016\/j.msard.2026.106976_bib0014","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/PPA.S118107","article-title":"An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug","volume":"11","author":"Munsell","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.msard.2026.106976_bib0007","unstructured":"Novartis Pharmaceuticals CanadaInc. Kesimpta Product Monograph (13 March 2024). https:\/\/pdf.hres.ca\/dpd_pm\/00074926.PDF."},{"issue":"17_supplement_1","key":"10.1016\/j.msard.2026.106976_bib0024","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1212\/WNL.0000000000206274","article-title":"Longer-term (Up to 6 Years) efficacy of Ofatumumab in people with recently diagnosed and treatment-naive relapsing multiple sclerosis (S31.003)","volume":"102","author":"Pardo","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2026.106976_bib0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12883-023-03100-1","article-title":"Patient and nurse preference for Sensoready autoinjector pen versus other autoinjectors in multiple sclerosis: results from a pilot multicenter survey","volume":"23","author":"Ross","year":"2023","journal-title":"BMC Neurol"},{"issue":"1","key":"10.1016\/j.msard.2026.106976_bib0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","article-title":"Multiple sclerosis: time for early treatment with high-efficacy drugs","volume":"271","author":"Selmaj","year":"2024","journal-title":"J. Neurol"},{"issue":"7","key":"10.1016\/j.msard.2026.106976_bib0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","article-title":"Early aggressive treatment approaches for multiple sclerosis","volume":"23","author":"Simpson","year":"2021","journal-title":"Curr. Treat Options Neurol"},{"key":"10.1016\/j.msard.2026.106976_bib0016","series-title":"Consortium of multiple sclerosis centers; May 29, 2024","article-title":"Real-world persistence and adherence to Ofatumumab vs Ocrelizumab in patients with multiple sclerosis","author":"Tai","year":"2024"},{"issue":"5","key":"10.1016\/j.msard.2026.106976_bib0003","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3111\/13696998.2015.1134546","article-title":"The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis","volume":"19","author":"Thomas","year":"2016","journal-title":"J. Med. Econ"},{"key":"10.1016\/j.msard.2026.106976_bib0012","series-title":"Real-world Australian experience With Ofatumumab in the MSBase registry. ECTRIMS annual scientific meeting 2024 abstracts","author":"Van der","year":"2024"},{"issue":"17_supplement_1","key":"10.1016\/j.msard.2026.106976_bib0020","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1212\/WNL.0000000000205570","article-title":"Longer-term safety and efficacy of Ofatumumab in people with relapsing multiple sclerosis for up to 6 years (P9-6.010)","volume":"102","author":"Wiendl","year":"2024","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2026.106976_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/13524585241307165","article-title":"Ofatumumab-exposed breastfeeding in multiple sclerosis patients - PubMed","volume":"31","author":"Witt","year":"2025","journal-title":"Mult. Scler"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600012X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600012X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:52:56Z","timestamp":1780415576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482600012X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"alternative-id":["S221103482600012X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.106976","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A real-world study on persistence with ofatumumab in Canadian patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.106976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Novartis Pharmaceuticals Canada Inc. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106976"}}